Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13108981 | 0.78 | TSHR (0.35) | TSHRNPSR1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL2152882 | 0.76 | TSHR (0.34) | TSHRNPSR1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL5960637 | 0.76 | ALDH1A1 (0.39) | TSHRNPSR1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL28481264 | 0.76 | TSHR (0.34) | TSHRNPSR1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL14530109 | 0.76 | TSHR (0.34) | TSHRNPSR1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL30401051 | 0.74 | ALDH1A1 (0.35) | TSHRTHRBALDH1A1 | |
| SCHEMBL1784672 | 0.74 | LMNA (0.34) | ALDH1A1 | |
| SCHEMBL4613660 | 0.72 | THRB (0.35) | THRBALDH1A1L3MBTL1 | |
| SCHEMBL13898883 | 0.72 | THRB (0.35) | THRBALDH1A1L3MBTL1 | |
| SCHEMBL2167176 | 0.72 | THRB (0.35) | TSHRTHRBALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119677695-A | Method and apparatus for destruction and defluorination of perfluoro and polyfluoroalkyl species (PFAS), fluorotelomers and other persistent organic contaminants | 克拉罗斯技术股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-116148403-A | Micro-extraction method for rapidly extracting short-chain perfluoro and polyfluoroalkyl compound in water sample | 上海交通大学 | 2023-05-23 | — | — | CN | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| EP-0583540-A1 | Synthesis of desflurane | Anaquest, Inc. (US) | 1994-02-23 | — | — | EP | claimed |
| US-5205914-A | Synthesis of desflurane | ANAQUEST, INC. (US) | 1993-04-27 | — | — | US | claimed |
| JP-6087777-A | — | — | None | — | — | JP | disclosed |
| CN-119677695-A | Method and apparatus for destruction and defluorination of perfluoro and polyfluoroalkyl species (PFAS), fluorotelomers and other persistent organic contaminants | 克拉罗斯技术股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240291009-A1 | METHOD FOR PURIFYING TREATMENT TARGET SOLUTION | AGC Inc. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4417582-A1 | METHOD FOR PURIFYING TREATMENT TARGET SOLUTION | AGC Inc. (JP) | 2024-08-21 | — | — | EP | disclosed |
| CN-118176168-A | Method for purifying liquid to be treated | ＡＧＣ株式会社 | 2024-06-11 | — | — | CN | disclosed |
| US-5350646-A | Ionically conductive polymeric materials | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1994-09-27 | — | — | US | disclosed |
| JP-H0687777-A | SYNTHESIS OF DESFLURANE | ANAQUEST INC | 1994-03-29 | — | — | JP | disclosed |
| EP-0583540-A1 | Synthesis of desflurane | Anaquest, Inc. (US) | 1994-02-23 | — | — | EP | disclosed |
| EP-0331367-B1 | Liquid crystal compounds having fluoroalkyl radical | SHOWA SHELL SEKIYU (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5205914-A | Synthesis of desflurane | ANAQUEST, INC. (US) | 1993-04-27 | — | — | US | disclosed |
| US-5051527-A | Liquid crystal compounds having fluoroalkyl radical | SHOWA SHELL SEKIYU K.K. (JP) | 1991-09-24 | — | — | US | disclosed |
| EP-0331367-A2 | Liquid crystal compounds having fluoroalkyl radical | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | TSHR 756/4885NPSR1 628/4885THRB 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.